595 related articles for article (PubMed ID: 31799745)
1. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
[TBL] [Abstract][Full Text] [Related]
2. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
3. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP
Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822
[TBL] [Abstract][Full Text] [Related]
4. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
[TBL] [Abstract][Full Text] [Related]
5. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
Liu C; Armstrong C; Zhu Y; Lou W; Gao AC
Oncotarget; 2016 May; 7(22):32210-20. PubMed ID: 27049719
[TBL] [Abstract][Full Text] [Related]
6. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
7. Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.
Tummala R; Nadiminty N; Lou W; Evans CP; Gao AC
Prostate; 2016 Apr; 76(5):445-55. PubMed ID: 26714839
[TBL] [Abstract][Full Text] [Related]
8. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
[TBL] [Abstract][Full Text] [Related]
9. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.
Lombard AP; Liu L; Cucchiara V; Liu C; Armstrong CM; Zhao R; Yang JC; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2018 Oct; 17(10):2197-2205. PubMed ID: 29891490
[TBL] [Abstract][Full Text] [Related]
10. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
11. Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
Naiki-Ito A; Naiki T; Kato H; Iida K; Etani T; Nagayasu Y; Suzuki S; Yamashita Y; Inaguma S; Onishi M; Tanaka Y; Yasui T; Takahashi S
Carcinogenesis; 2020 Aug; 41(8):1145-1157. PubMed ID: 31805186
[TBL] [Abstract][Full Text] [Related]
12. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
14. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
15. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
17. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
[TBL] [Abstract][Full Text] [Related]
19. Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
Sasaki T; Yoshikawa Y; Kageyama T; Sugino Y; Kato M; Masui S; Nishikawa K; Inoue T
Prostate; 2023 Mar; 83(4):364-375. PubMed ID: 36479717
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
Leung JK; Tam T; Wang J; Sadar MD
Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
